Human Anatomy and Embryology Unit, Molecular Oncology and Embryology Laboratory, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain.
J Surg Oncol. 2011 Apr;103(5):411-5. doi: 10.1002/jso.21847. Epub 2010 Dec 29.
MicroRNAs are novel regulators of gene expression that are linked to the main oncogene networks, including the p53 pathway. p53 regulates the maturation process of miR-16 and miR-143. We analyzed the role as prognostic markers of miR-16 and miR-143 in 70 non-small-cell lung cancer (NSCLC) patients.
MicroRNAs were analyzed by TaqMan MicroRNA assays. Disease-free survival (DFS) and overall survival (OS) were examined using Kaplan-Meier curves with log-rank tests and the Cox proportional hazard model.
When patients were classified in three groups according to their miR-16 expression levels, those with normal levels had the best outcome while those with high levels had the worst. DFS was 22.4 months for patients with high levels, 71.8 months for those with normal levels, and 55.8 months for those with low levels (P = 0.05). OS was 23.9 months for patients with high levels, 97.6 months for those with normal levels, and 63.5 months for those with low levels (P < 0.001). In the multivariate analyses, high miR-16 levels emerged as an independent prognostic factor for poor DFS (P = 0.001) and OS (<0.001).
Our results provide the first hints that miR-16 levels in tumor samples may be a prognostic marker in NSCLC.
MicroRNAs 是一种新型的基因表达调控因子，与包括 p53 通路在内的主要癌基因网络有关。p53 调节 miR-16 和 miR-143 的成熟过程。我们分析了 miR-16 和 miR-143 在 70 名非小细胞肺癌（NSCLC）患者中的预后标志物作用。
采用 TaqMan MicroRNA 检测试剂盒分析 MicroRNAs。通过 Kaplan-Meier 曲线和对数秩检验以及 Cox 比例风险模型来检查无病生存（DFS）和总生存（OS）。
当根据 miR-16 表达水平将患者分为三组时，正常水平组的患者预后最好，而高水平组的患者预后最差。DFS 方面，高水平组患者为 22.4 个月，正常水平组为 71.8 个月，低水平组为 55.8 个月（P=0.05）。OS 方面，高水平组患者为 23.9 个月，正常水平组为 97.6 个月，低水平组为 63.5 个月（P<0.001）。在多变量分析中，高 miR-16 水平是 DFS（P=0.001）和 OS（<0.001）不良的独立预后因素。
我们的研究结果首次提示肿瘤样本中的 miR-16 水平可能是非小细胞肺癌的一种预后标志物。
